Celldex Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.
Current Price
$31.34
-3.42%Profile
Valuation (TTM)
Market Cap$2.09B
P/E-7.35
EV—
P/B3.96
Shares Out66.57M
P/Sales2408.99
Revenue$866000.00
EV/EBITDA—
Celldex Therapeutics Inc (CLDX) Stock Analysis
Market Cap$2.09B
Current Price$31.34
P/E Ratio-7.35
Forward P/E—
PEG Ratio-0.16
EPS$-3.90
Book Value$7.92
P/B Ratio3.96
CLDX Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 27M
Revenue
4M
FY19
7M
FY20
5M
FY21
2M
FY22
7M
FY23
7M
FY24
2M
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
CLDX 52-Week Range
$18.66
$34.55
50-Day MA: $32.07200-Day MA: $27.07
Did you know?
CLDX's revenue grew at a -13.0% CAGR over the last 6 years.
Celldex Therapeutics Inc (CLDX) Financial Summary
Celldex Therapeutics Inc (CLDX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $31.34 with a market capitalization of $2.09B.
Key valuation metrics include a P/E ratio of -7.35, price-to-book ratio of 3.96, and EPS of $-3.90. The company reports a profit margin of -32753.6% and return on equity of -53.8%.
CLDX Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $2.09B |
| P/E Ratio | -7.35 |
| EPS | $-3.90 |
| P/B Ratio | 3.96 |
| P/S Ratio | 2408.99 |
| Profit Margin | -32753.6% |
| Return on Equity | -53.8% |
| Debt/Equity | 0.00 |
CLDX Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $3.57M | $-50.88M |
| FY20 | $7.42M | $-59.78M |
| FY21 | $4.65M | $-70.51M |
| FY22 | $2.36M | $-112.33M |
| FY23 | $6.88M | $-141.43M |
| FY24 | $7.02M | $-157.86M |
| FY25 | $1.54M | $-258.76M |
CLDX Quality Indicators
Celldex Therapeutics Inc maintains a profit margin of -32753.6% and an operating margin of -18599.8%. Return on equity stands at -53.8%. The current ratio is 10.49. Debt-to-equity ratio is 0.00.
About Celldex Therapeutics Inc
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.
CLDX Free Cash Flow
Celldex Therapeutics Inc generated $-213.66M in trailing twelve-month free cash flow, representing an FCF yield of -10.24%. This low FCF yield may reflect heavy reinvestment or growth spending.
CLDX Shares Outstanding
Celldex Therapeutics Inc has 0.07 billion shares outstanding at a share price of $31.34, giving it a market capitalization of $2.09B.